



# NOVELTY: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice

Renaud Louis<sup>1</sup>, Gilles Louis<sup>2</sup> and Olivier Bonhomme <sup>1</sup>

<sup>1</sup>Dept of Pneumology, CHU Liege, Liege, Belgium. <sup>2</sup>Dept of Public Health, University of Liege, Liege, Belgium.

Corresponding author: Renaud Louis ([R.Louis@chuliege.be](mailto:R.Louis@chuliege.be))



Shareable abstract (@ERSpublications)

**NOVELTY is a prospective real life observational study that investigates asthma, COPD and asthma/COPD overlap over a period of years with the purpose to relate phenotype and endotype to clinical outcomes and disease trajectories** <https://bit.ly/3qERZRD>

**Cite this article as:** Louis R, Louis G, Bonhomme O. NOVELTY: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice. *Eur Respir J* 2021; 58: 2100627 [DOI: 10.1183/13993003.00627-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2021. For reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 2 March 2021  
Accepted: 2 March 2021

Asthma and COPD are two common chronic airway diseases associated with high morbidity and mortality [1, 2]. It is estimated that approximately 20% of asthma and COPD have diagnosis or features of both [3]. There is growing appreciation of the need to tease out phenotypes and endotypes across the spectrum of chronic airway diseases [4, 5], to evolve towards precision medicine [6, 7]. While there have been recent large cohort studies following either severe asthma [8] or COPD [9], there is paucity of large real life longitudinal studies investigating both asthma and COPD together with the asthma/COPD overlap across the all disease severity spectrum without any predetermined pharmacological intervention.